Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/19/2011

showed exenatide, at and above therapeutic levels, did not prolong the corrected QT interval in healthy individuals
  • Announced that the FDA assigned a new Prescription Drug User Fee Act (PDUFA) action date of January 28, 2012 for BYDUREON
  • Presented compelling efficacy and safety data at the European Association for the Study of Diabetes (EASD) Annual Meeting from the DURATION-3 and -4 trials. The studies demonstrated that patients treated with BYDUREON experienced significant improvements in select cardiovascular risk factors, including improvements in composite endpoints related to body weight, abnormal blood pressure and abnormal lipid levels, in comparison to patients who received commonly prescribed diabetes treatments

  • Obesity Program

  • Announced the discontinuation of the pramlintide/metreleptin development program for obesity. The joint decision between Amylin and Takeda Pharmaceuticals Limited was based on a commercial reassessment of the pramlintide/metreleption program. The companies continue to evaluate other assets as potential candidates for the treatment of obesity and related indications under the terms of their existing collaboration agreement

  • Quarter Ended September 30, 2011Net product sales of $155.1 million for the quarter ended September 30, 2011 include $128.1 million for BYETTA® (exenatide) injection and $27.0 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $154.0 million, consisting of $132.4 million for BYETTA and $21.6 million for SYMLIN for the same period in 2010. Revenues under collaborative agreements were $19.9 million for the quarter ended September 30, 2011, and included a $15.0 million milestone payment from Lilly in connection with the launch of BYDUREON in the European Union in July, compared to $2.1 million for the same period in 2010.

    Selling, general and administrative expenses decreased to $63.1 million for the q
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Amylin Pharmaceuticals to Webcast Third Quarter Results
    2. Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    3. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
    4. Amylin Pharmaceuticals to Webcast Second Quarter Results
    5. U.S. District Court Rules in Favor of Lilly in Amylin Litigation
    6. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
    7. Amylin Pharmaceuticals Obtains Temporary Restraining Order Against Eli Lilly
    8. Lilly Comments on Court Ruling in Amylin Litigation
    9. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
    10. Lilly Provides Its Perspective in Response to Amylin Lawsuit
    11. Lilly Provides Statement in Response to Amylin Lawsuit
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)... 31, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... Chicago -based Rush University Medical Center in ... escalating doses of AST-OPC1 (oligodendrocyte progenitor cells) in ... cervical spinal cord injury (SCI). This represents the ...
    (Date:8/31/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... media and a related cloud hosted ... smart shippers ("BioLife" or the "Company"), today ... biopharmaceutical company focused on developing and commercializing novel ...
    (Date:8/28/2015)... , Aug. 28, 2015  With the heroin ... reaching deadlier heights, Jacksonville -based Lakeview ... Hemphill is helping to explain why fentanyl is ... approximately 40 to 50 times more potent than pharmaceutical ... users as heroin, the risk of death skyrockets. ...
    Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2
    ... (OTCQX: DATA), a technology and services company focused on global ... its Vice President of Research and Development, Chris Wilke, has ... 2009 Society for Clinical Data Management (SCDM) Annual Conference which ... Mr. Wilke will be discussing Is 100% EDC Realistic? ...
    ... ThermalTherapeutic Systems, Inc., developers of a highly ... today the completion of $2.75 Million Series A ... funding by the Pittsburgh Life Sciences Greenhouse, and ... investments by the Pittsburgh Life Sciences Greenhouse and ...
    Cached Medicine Technology:DATATRAK to Present at 2009 SCDM Annual Conference 2DATATRAK to Present at 2009 SCDM Annual Conference 3ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures 2
    (Date:8/31/2015)... Angeles, CA (PRWEB) , ... August 31, 2015 , ... When it comes to undergoing ... to the top of the head. Adding more volume to the hair on top ... procedure for patients who have a good amount of donor hair on other areas of ...
    (Date:8/31/2015)... ... , ... The Lisle family law firm of Momkus McCluskey, LLC ... peers to earn a “Leading Lawyers” distinction. , The “Leading Lawyers” ... Illinois. The nomination process is based on statewide peer survey nominations and the approval ...
    (Date:8/31/2015)... Dayton, Ohio (PRWEB) , ... August 31, 2015 ... ... Jenny Michael as Vice President, Marketing and Corporate Communications. In this capacity, Michael ... , CareSource is an industry leader in consumer-focused programs that have contributed ...
    (Date:8/31/2015)... Carolina (PRWEB) , ... August 31, 2015 , ... The ... Laurels on Tuesday, September 1. , “Alive Inside” shadows a social worker who ... & MEMORY?.” , “It’s a documentary about bringing music to residents in health care ...
    (Date:8/31/2015)... ... 31, 2015 , ... David L. Chalnick, M.D., the medical ... first doctors in the area to perform minimally invasive hip replacement surgery. Over ... recovery, decreased immediate and long-term pain, and an accelerated return to normal activity. ...
    Breaking Medicine News(10 mins):Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4
    ... if an individual has a variant form of a gene ... The taste receptor gene, called TAS2R16 is located on chromosome ... of Medicine have studied more than 262 DNA samples, before ... a study called Collaborative Study of the Genetics of Alcoholism ...
    ... substantial improvement in the bone density later in life // ... found to have weaker bones at 9 years of age. ... Vitamin D into a more active form that can be ... or exposure of children to sunlight was found to result ...
    ... professor of psychology at south-western university and a graduate student ... effect on the sexual behaviour of female rats. ... the first to determine the effects of caffeine on the ... the relationship between caffeine and sex. ,The researchers ...
    ... to exist in radioactive waste, hot springs and fecal ... inside the human stomach. // This finding could eventually ... newer treatment strategies. ,The bacteria 'Helicobacter pylori', ... largely blamed for causing peptic ulcers. However the exact ...
    ... a unique way to help people beat the winter blues-by setting ... // . ,The Dana Cafe offers free 20-minute light ... ,Up to 500,000 people, a majority of them women, are believed ... more common in the northern latitudes where the Sun is not ...
    ... Bruce Wilson, a Milwaukee Cardiologist, and Chief of the ... System is in dire need of a shot in ... the ills of prevailing healthcare systems, was nipped in ... Wilson, in an opinion write-up in The Wall Street ...
    Cached Medicine News:Health News:Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk 2Health News:Maternal Vitamin D Supplementation Promises Healthy Bones In Child 2
    The Natural Selection family of specialty allografts is spinal concepts response to surgeon requests for spinal allograft devices to eliminate the need for painful autograft harvesting....
    Transcranial vascular DWL doppler....
    Transcranial vascular DWL doppler....
    ... Neurocare is a full-featured physiologic testing system offered ... contains many of the features of our flagship ... economical price. , ,The smaller size of the ... environment, the physician's office, a mobile service or ...
    Medicine Products: